Treatment with mTOR inhibitors is effective in many manifestations of TSC, such as SEGA tumors, kidney AML, LAM, and epilepsy; however, usually only a partial response is observed [4,5,6,24]. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.